Kishor Bhatia
Vermögen: - $ am 31.08.2026
Vermögen: - $ am 31.08.2026
Kishor G.
Bhatia currently works at Lantern Pharma, Inc., as Chief Scientific Officer from 2019.
Dr. Bhatia also formerly worked at National Cancer Institute, as Director-AIDS Malignancy Program from 2007 to 2016 and Georgetown University, as Research Assistant Professor from 1985 to 1989.
Dr. Bhatia received his doctorate degree from the University of Mumbai and undergraduate degree from the University of Pune.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
LANTERN PHARMA, INC. -.--% | 17.04.2026 | 0 ( -.--% ) | - $ | 31.08.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| LANTERN PHARMA INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.12.2019 |
| Unternehmen | Position | Ende |
|---|---|---|
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous Conducts research projects & awards grants for cancer research | Corporate Officer/Principal | 01.07.2016 |
Georgetown University
Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01.01.1989 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
University of Mumbai
University of Mumbai Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Georgetown University
Georgetown University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
National Cancer Institute
National Cancer Institute Investment Trusts/Mutual FundsMiscellaneous Conducts research projects & awards grants for cancer research | Miscellaneous |
University of Pune
University of Pune Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lantern Pharma, Inc.
Lantern Pharma, Inc. Pharmaceuticals: MajorHealth Technology Develops cancer drug from advanced genomics and artificial intelligence | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen